Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Acute lymphoblastic leukemia
Ponatinib (BCR-ABL TKI) + blinatumomab (CD19xCD3 BiTE) improves 24-month EFS vs imatinib-chemo in Ph+ ALL
Ponatinib is a third-generation BCR-ABL tyrosine kinase inhibitor and blinatumomab is a CD19xCD3 bispecific T-cell engager; this Phase 3 GIMEMA ALL2820/LAL2820 trial (NCT04722848) randomized frontline adult Ph+ ALL…
NCT04722848 - Trial result Spotlight
Non-small cell lung cancer
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC
CHORUS (NCT04905316) tested canakinumab, an anti–interleukin-1β monoclonal antibody intended to blunt protumor inflammation, given with concurrent chemoradiotherapy (cCRT) and continued alongside anti–PD-L1…
NCT04905316 - Trial result Spotlight
Lymphoma
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL
Glofitamab is a CD3×CD20 T-cell–engaging bispecific antibody added to polatuzumab vedotin (CD79b ADC) plus R-CHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, prednisone) in a multicenter Phase II frontline…
NCT05800366 - Trial result Spotlight
Ovarian cancer
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy
Sofetabart mipitecan (Sofe-M) is an FRα-targeting antibody–drug conjugate engineered to broaden activity beyond “FRα-high only” tumors and potentially avoid the ocular toxicity seen with mirvetuximab soravtansine…
NCT07213804 - Trial result Spotlight
Breast cancer
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer
Giredestrant is an oral selective estrogen receptor degrader (SERD) designed to overcome ER-driven endocrine resistance, and everolimus is an oral mTOR inhibitor targeting the PI3K–AKT–mTOR pathway; the all-oral…
NCT05306340 - Trial result Spotlight
Bladder and urothelial cancer
GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC
GemBCG combines intravesical gemcitabine (a DNA synthesis–inhibiting antimetabolite chemotherapy) with intravesical BCG (live-attenuated mycobacterial immunotherapy) in an alternating schedule to intensify local…
NCT04179162 - Trial result Spotlight
Chronic lymphocytic leukemia
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) improves long-term OS/PFS in 1L CLL, with more progression-free time without grade 3/4 AEs
Fixed-duration ibrutinib-venetoclax is an all-oral BTK/BCL-2 doublet evaluated in the Phase 3 GLOW trial (NCT03462719) in older/comorbid, previously untreated CLL, randomized vs chlorambucil-obinutuzumab (n=106 vs…
NCT03462719 - Trial result Spotlight
Lymphoma
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma
Pembrolizumab-GVD combines pembrolizumab (anti–PD-1) with gemcitabine/vinorelbine/liposomal doxorubicin chemotherapy as PET-adaptive salvage to bridge transplant-eligible relapsed/refractory classical Hodgkin…
NCT03618550 - Trial result Spotlight
Brain and CNS tumors
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets
Cesium-131 collagen tile-based radiation therapy (TBRT; intraoperative brachytherapy that delivers focal radiation immediately after resection) was compared with standard post-operative stereotactic radiation therapy…
NCT04365374 - New trial Spotlight
Prostate cancer
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement
Janux Therapeutics’ first-in-human Phase 1, open-label, multicenter study evaluates JANX013 plus JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a PSMA-directed,…
NCT07813637 First-in-human - New trial Spotlight
Ovarian cancer
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer
AstraZeneca’s TREVI-OC-02 is a randomized, open-label Phase 3 trial comparing torvutatug samrotecan (torvu-sam) plus bevacizumab with bevacizumab alone as first-line maintenance. Torvu-sam is a folate receptor alpha…
NCT07851025 Registrational - New trial Spotlight
Stomach and esophageal cancer
Phase 3 ASP2138 CLDN18.2×CD3 T-cell engager adds to first-line treatment for gastric and GEJ cancer
Astellas Pharma Global Development is running this randomized, double-blind Phase 3 study in locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction…
NCT07673887 Registrational - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 DAYBreak CLL-306 compares bexobrutideg BTK degradation with pirtobrutinib after covalent BTK inhibition
Nurix Therapeutics’ randomized, open-label, multicenter DAYBreak CLL-306 study compares bexobrutideg (NX-5948), a small-molecule Bruton tyrosine kinase protein degrader, with pirtobrutinib, Eli Lilly’s noncovalent…
NCT07516093 Registrational - New trial Spotlight
Colorectal cancer
Phase 3 STELLAR-316 tests zanzalintinib with or without pembrolizumab for ctDNA-positive, scan-negative colorectal cancer
Exelixis’ randomized Phase 3 STELLAR-316 study enrolls resected stage II/III colon or rectal adenocarcinoma that is MSS or MSI-low/pMMR, with molecular residual disease detected by the Signatera ctDNA assay after…
NCT07750158 Registrational - Trial result Spotlight
Stomach and esophageal cancer
Evorpacept (CD47 blocker) + TRP lifts ORR in 2L/3L HER2+ gastric/GEJ—PFS flat in ITT
Evorpacept blocks the CD47–SIRPα interaction to enhance macrophage-mediated tumor-cell killing, here combined with trastuzumab + ramucirumab + paclitaxel (TRP). In the randomized Phase II portion of ASPEN-06…
NCT05002127 - Trial result Spotlight
Melanoma
Lifileucel produces confirmed responses in 2 of 3 treated adolescents with ICI-refractory metastatic melanoma
Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy (adult US accelerated approval) given after cyclophosphamide/fludarabine lymphodepletion and followed by up to six doses of high-dose IL-2; here…
NCT06566092 - New trial Spotlight
Bladder and urothelial cancer
Phase 2/3 Ivonescimab PD-1×VEGF bispecific antibody plus enfortumab vedotin Nectin-4 ADC in la/mUC
HARMONi-GU1 (NCT07815665) is a randomized, open-label, multicenter Phase 2/3 study testing whether ivonescimab + enfortumab vedotin (EV) can outperform pembrolizumab + EV as first-line therapy for unresectable…
NCT07815665 Registrational - New trial Spotlight
Melanoma
Phase 3 darovasertib PKC inhibitor plus crizotinib c-MET/ALK inhibitor in adjuvant uveal melanoma
IDEAYA Biosciences’ OptimUM-11 is a randomized, multi-center, open-label Phase 3 study testing whether adjuvant darovasertib (IDE196; a small-molecule protein kinase C inhibitor) combined with crizotinib (a…
NCT07804186 Registrational - New trial Spotlight
Melanoma
Phase 3 iSCIB1+ gp100/TRP-2 DNA vaccine adds melanoma antigen targeting to PD-1/CTLA-4 blockade.
Scancell Ltd’s adaptive, multicenter Phase 3 trial randomizes adults with unresectable Stage III/IV melanoma to iSCIB1+ (a DNA “Immunobody” vaccine encoding melanoma antigens gp100 and TRP-2 to drive antigen-specific…
NCT07815574 Registrational - New trial Spotlight
Brain and CNS tumors
Phase 1 SRN-101 intratumoral AAV–IFNβ immuno-gene therapy in recurrent high-grade glioma.
This first-in-human, single-arm, window-of-opportunity Phase 1 study tests SRN-101, an adeno-associated virus (AAV) gene therapy engineered to express interferon-beta (IFNβ) locally in tumor tissue, aiming to…
NCT07826949 First-in-human - New trial Spotlight
Ovarian cancer
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload
AstraZeneca’s TREVI-OC-03 is a randomized, open-label Phase 3 maintenance study testing torvutatug samrotecan (torvu-sam; AZD5335), a folate receptor alpha (FRα/FOLR1)–directed monoclonal antibody–drug conjugate…
NCT07816666 Registrational - New trial Spotlight
Colorectal cancer
Phase 2 VVD-133214 WRN helicase covalent inhibitor + pembrolizumab (PD-1 antibody) in MSI/dMMR CRC
This randomized, open-label Phase 2 study tests whether adding VVD-133214 (RO7589831)—a first-in-class, covalent allosteric inhibitor of Werner helicase (WRN)—can improve outcomes versus pembrolizumab alone in…
NCT07811193 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Savolitinib (MET TKI) + osimertinib boosts ORR to 49% when MET is truly “high” (IHC3+/≥90% and/or FISH10+)
Savolitinib is an oral, selective MET tyrosine kinase inhibitor being combined with osimertinib (3rd-gen EGFR TKI) to overcome MET-driven resistance after first-line osimertinib in EGFR-mutated advanced NSCLC in the…
NCT03778229 - Trial result Spotlight
Head and neck cancer
PDS0101 (HPV16-targeted immunotherapy) + pembrolizumab drives 34% ORR and 39.3-mo mOS in 1L HPV16+ R/M HNSCC
PDS0101 is a therapeutic HPV16-targeted immunotherapy designed to generate HPV16-specific T-cell responses, here combined with the PD-1 inhibitor pembrolizumab in VERSATILE-002, a Phase 2 open-label, multicenter,…
NCT04260126 - Trial result Spotlight
Acute lymphoblastic leukemia
Blinatumomab (CD19xCD3 BiTE) Replaces 2 Chemo Blocks and Improves 4-year EFS in Pediatric High-Risk B-ALL
Blinatumomab (Blincyto), a CD19xCD3 bispecific T-cell engager that redirects T cells to kill CD19+ B-lineage blasts, was tested in the randomized Phase 3 AIEOP-BFM ALL 2017 study (EudraCT 2016-001935-12; NCT03643276)…
NCT03643276 - New trial Spotlight
Prostate cancer
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18
Fred Hutchinson Cancer Center is running a first-in-human Phase 1 dose-escalation/expansion study of FH-STEAP1 IL-18 CAR T cells, an autologous anti-STEAP1 CAR-T therapy engineered to secrete IL-18 (a…
NCT07803653 First-in-human - New trial Spotlight
Colorectal cancer
Phase 2 trastuzumab rezetecan (SHR-A1811) HER2-directed topoisomerase I inhibitor ADC in 1L mCRC
HORIZON-CRC221 is a global, multicenter, randomized, dose-optimization Phase 2 study testing two dose levels of trastuzumab rezetecan (SHR-A1811)—a HER2-targeted monoclonal antibody–drug conjugate delivering a…
NCT07796763 Exploratory - New trial Spotlight
Lymphoma
Phase 2 BOSon tests zanubrutinib + obinutuzumab + sonrotoclax in frontline MCL
Memorial Sloan Kettering Cancer Center is running this Phase 2 study of a chemotherapy-free, MRD-guided frontline regimen for transplant-ineligible patients with stage II–IV mantle cell lymphoma. Treatment combines…
NCT07799220 Exploratory - Trial result Spotlight
Acute lymphoblastic leukemia
Everolimus (mTOR inhibitor) + NECTAR salvage delivers 75% ORR in pediatric/AYA R/R T-ALL/T-LL
Everolimus is an oral mTORC1 inhibitor combined here with NECTAR chemotherapy (nelarabine + cyclophosphamide + etoposide) in the multisite ENCERT Phase 1 dose-escalation study in children/young adults with…
NCT03328104 - Trial result Spotlight
Ovarian cancer
Pembrolizumab (PD-1) + chemo → maintenance pembrolizumab + olaparib (PARP) extends PFS in BRCA–wild-type ovarian cancer
Pembrolizumab is an anti–PD-1 antibody and olaparib is a PARP inhibitor; in KEYLYNK-001 (ENGOT-OV43/GOG-3036; NCT03740165), patients with newly diagnosed stage III–IV BRCA1/2 non-mutated epithelial ovarian/primary…
NCT03740165
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.